C-reactive protein independently predicts survival in pancreatic neuroendocrine neoplasms
Standard
C-reactive protein independently predicts survival in pancreatic neuroendocrine neoplasms. / Nießen, Anna; Schimmack, Simon; Sandini, Marta; Fliegner, Dominik; Hinz, Ulf; Lewosinska, Magdalena; Hackert, Thilo; Büchler, Markus W; Strobel, Oliver.
In: SCI REP-UK, Vol. 11, No. 1, 09.12.2021, p. 23768.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - C-reactive protein independently predicts survival in pancreatic neuroendocrine neoplasms
AU - Nießen, Anna
AU - Schimmack, Simon
AU - Sandini, Marta
AU - Fliegner, Dominik
AU - Hinz, Ulf
AU - Lewosinska, Magdalena
AU - Hackert, Thilo
AU - Büchler, Markus W
AU - Strobel, Oliver
N1 - © 2021. The Author(s).
PY - 2021/12/9
Y1 - 2021/12/9
N2 - Pancreatic neuroendocrine neoplasms (pNEN) are highly variable in their postresection survival. Determination of preoperative risk factors is essential for treatment strategies. C-reactive protein (CRP) has been implicated in the pathogenesis of pNEN and shown to be associated with survival in different tumour entities. Patients undergoing surgery for pNEN were retrospectively analysed. Patients were divided into three subgroups according to preoperative CRP serum levels. Clinicopathological features, overall and disease-free survival were assessed. Uni- and multivariable survival analyses were performed. 517 surgically resected pNEN patients were analysed. CRP levels were significantly associated with relevant clinicopathological parameters and prognosis and were able to stratify subgroups with significant and clinically relevant differences in overall and disease-free survival. In univariable sensitivity analyses CRP was confirmed as a prognostic factor for overall survival in subgroups with G2 differentiation, T1/T2 and T3/T4 tumour stages, patients with node positive disease and with and without distant metastases. By multivariable analysis, preoperative CRP was confirmed as an independent predictor of postresection survival together with patient age and the established postoperative pathological predictors grading, T-stage and metastases. Preoperative serum CRP is a strong predictive biomarker for both overall and disease free survival of surgically resected pNEN. CRP is associated with prognosis independently of grading and tumour stage and may be of additional use for treatment decisions.
AB - Pancreatic neuroendocrine neoplasms (pNEN) are highly variable in their postresection survival. Determination of preoperative risk factors is essential for treatment strategies. C-reactive protein (CRP) has been implicated in the pathogenesis of pNEN and shown to be associated with survival in different tumour entities. Patients undergoing surgery for pNEN were retrospectively analysed. Patients were divided into three subgroups according to preoperative CRP serum levels. Clinicopathological features, overall and disease-free survival were assessed. Uni- and multivariable survival analyses were performed. 517 surgically resected pNEN patients were analysed. CRP levels were significantly associated with relevant clinicopathological parameters and prognosis and were able to stratify subgroups with significant and clinically relevant differences in overall and disease-free survival. In univariable sensitivity analyses CRP was confirmed as a prognostic factor for overall survival in subgroups with G2 differentiation, T1/T2 and T3/T4 tumour stages, patients with node positive disease and with and without distant metastases. By multivariable analysis, preoperative CRP was confirmed as an independent predictor of postresection survival together with patient age and the established postoperative pathological predictors grading, T-stage and metastases. Preoperative serum CRP is a strong predictive biomarker for both overall and disease free survival of surgically resected pNEN. CRP is associated with prognosis independently of grading and tumour stage and may be of additional use for treatment decisions.
KW - Aged
KW - Biomarkers, Tumor
KW - C-Reactive Protein
KW - Carcinoma, Neuroendocrine/blood
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Male
KW - Middle Aged
KW - Multivariate Analysis
KW - Neoplasm Grading
KW - Neoplasm Staging
KW - Pancreatic Neoplasms/blood
KW - Prognosis
KW - Proportional Hazards Models
KW - ROC Curve
U2 - 10.1038/s41598-021-03187-x
DO - 10.1038/s41598-021-03187-x
M3 - SCORING: Journal article
C2 - 34887479
VL - 11
SP - 23768
JO - SCI REP-UK
JF - SCI REP-UK
SN - 2045-2322
IS - 1
ER -